

CAR-based immunotherapies for hematological cancers: new targets for old problems



12 de mayo de 2021 //16:00 horas

Moderador: Dr. Pere Barba. H. Vall de Hebron.

- **Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in Multiple Myeloma –**
Dr. José Antonio Pérez Simón, Head of Hematology, Hospital Virgen del Rocío, Sevilla (Spain)
- **Enhancing and Engineering NK Cells for Cancer Immunotherapy. –**
Dr. Todd Fehniger, Professor of Medicine, Washington University School of Medicine, Saint Louis, MO, USA. - tfehnige@wustl.edu

Con la colaboración de

